# AGENDA

**Wednesday, 4 September 2019**

<table>
<thead>
<tr>
<th>Time (CEST)</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
<th>Learning Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:20-09:30</td>
<td>Welcome Remarks</td>
<td>Najat Mokhtar-DDG NA May Abdel-Wahab-DIR NAHU</td>
<td>International Atomic Energy Agency</td>
<td>In Vienna</td>
<td></td>
</tr>
<tr>
<td>09:30-09:40</td>
<td>Conference Introduction</td>
<td>Diana Paez-SH NMDI</td>
<td>International Atomic Energy Agency</td>
<td>In Vienna</td>
<td></td>
</tr>
<tr>
<td>09:40-10:00</td>
<td>What are the urologists' needs?</td>
<td>Jochen Walz</td>
<td>Institut Paoli Calmettes Cancer Centre- Marseilles, France</td>
<td>Remote access from France</td>
<td>1. Understand the global burden of prostate cancer; 2. Assess the needs and expectations of referring physicians when requesting a PET/CT scan; 3. Discuss the clinician's perspective in regard to the indications of radionuclide therapies (223 Radium and radiolabelled PSMA).</td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>PSMA and beyond</td>
<td>Stefano Fanti</td>
<td>University of Bologna - Italy</td>
<td>Remote access from Italy</td>
<td>1. Review the status of molecular imaging with regards to prostate cancer; 2. Discuss new approaches using personalized medicine for prostate cancer; 3. Analyse the impact of Ga-PSMA in the management of prostate cancer.</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Alpha therapies</td>
<td>Mike Sathekge</td>
<td>University of Pretoria - South Africa</td>
<td>In Vienna</td>
<td>1. Recognize the available radionuclide therapies for prostate cancer; 2. Analyse the different impacts in patient’s overall survival and disease-free survival; 3. Discuss the evidence-based data available.</td>
</tr>
<tr>
<td>10:40-12:10</td>
<td>Case review interactive session</td>
<td>Wim Oyen Mike Sathekge</td>
<td>Humanitas Milan - Italy University of Pretoria - South Africa</td>
<td>In Vienna</td>
<td>1. Practice relevant case scenarios; 2. Reconcile clinical knowledge with novel theranostic methods; 3. Demonstrate the role of theranostics in the management of prostate cancer.</td>
</tr>
<tr>
<td>12:10-12:30</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-12:40</td>
<td>Welcome Remarks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-13:20</td>
<td>The use of I-131 in DTC: Is there a right answer?</td>
<td>Markus Luster</td>
<td>University of Marburg - Germany</td>
<td>In Vienna</td>
<td>1. Analyse the different approaches in the management of a patient with DTC; 2. Discuss the appropriate uses of I-131 in patient management; 3. Review the challenges for administration of I-131.</td>
</tr>
<tr>
<td>13:20-14:45</td>
<td>International Panel</td>
<td>Mike Sathekge Irene Virgolini Siros Mirzaei</td>
<td>University of Pretoria - South Africa University of Innsbruck - Austria Wilhelminen Hospital - Austria</td>
<td>In Vienna</td>
<td>1. Discuss the multidisciplinary approach of DTC management; 2. Discuss the controversies surrounding using of I-131 in DTC treatment; 3. Analyse and recognise the new risk stratification system proposed by clinicians.</td>
</tr>
<tr>
<td>15:00-15:20</td>
<td>What are the clinician’s needs?</td>
<td>Francesco Giammarile</td>
<td>International Atomic Energy Agency - Austria</td>
<td>In Vienna</td>
<td>1. Describe the global burden of NET; 2. Recognize the clinician’s perspective in regards to the indications of radionuclide therapies; 3. Discuss new approaches using personalized medicine for neuroendocrine neoplasms.</td>
</tr>
</tbody>
</table>
15:20-15:40 Theranostics: the present (agonist) Lisa Bodei Memorial Sloan Kettering Cancer Center - USA Remote access from USA

1. Indicate the status of molecular imaging with regards to NET;
2. Analyse the different impacts in patient’s overall survival and disease-free survival;
3. Discuss the evidence-based data available.

15:40-16:00 Theranostics: the future (antagonist) Guillaume Nicolas University of Basel - Switzerland In Vienna

1. Review the development of radiolabelled somatostatin receptor antagonist for molecular imaging and radionuclide therapy of NET;
2. Analyse the differences compared to current imaging and therapy approaches with somatostatin receptor agonist with regard to imaging and therapy outcome;
3. Discuss the evidence-based data available.

16:00-17:30 Case review interactive session Irene Virgolini University of Innsbruck - Austria In Vienna

1. Practice relevant case scenarios;
2. Reconcile clinical knowledge with novel theranostic methods;
3. Demonstrate the role of theranostics in the management of NET.

17:30-17:50 Q&A
## Session III-B - Theranostic Applications in Neuroendocrine Tumours: Current Status and Trends

<table>
<thead>
<tr>
<th>Time (CEST)</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
<th>Learning Objectives</th>
</tr>
</thead>
</table>
| 09:30-09:50 | What are the clinician’s needs? | Francesco Giammarile | International Atomic Energy Agency - Austria | In Vienna | 1. Describe the global burden of NET;
2. Recognize the clinician’s perspective in regards to the indications of radionuclide therapies;
3. Discuss new approaches using personalized medicine for neuroendocrine neoplasms. |
| 09:50-10:10 | Theranostics: the present (agonist) | Lisa Bodei | Memorial Sloan Kettering Cancer Center - USA | Remote access from USA | 1. Indicate the status of molecular imaging with regards to NET;
2. Analyse the different impacts in patient’s overall survival and disease-free survival;
3. Discuss the evidence-based data available. |
| 10:10-10:30 | Theranostics: the future (antagonist) | Guillaume Nicolas | University of Basel - Switzerland | In Vienna | 1. Review the development of radiolabelled somatostatin receptor antagonist for molecular imaging and radionuclide therapy of NET;
2. Analyse the differences compared to current imaging and therapy approaches with somatostatin receptor agonist with regard to imaging and therapy outcome;
3. Discuss the evidence-based data available. |
| 10:30-12:00 | Case review interactive session | Irene Virgolini | University of Innsbruck - Austria | In Vienna | 1. Practice relevant case scenarios;
2. Reconcile clinical knowledge with novel theranostic methods;
3. Demonstrate the role of theranostics in the management of NET. |
| 12:00-12:20 |  |  |  |  |  |
| 12:45-13:15 | Where we are | Markus Luster | University of Marburg - Germany | In Vienna | 1. Discuss new trends in theranostics;
2. Discuss how to disseminate innovative personalized medicine;
3. Discuss the economic and public health impact on advancing theranostic approaches. |
| 13:15-13:45 | Where are we going? | Giuliano Mariani | University of Pisa - Italy | Remote access from Italy | 1. Discuss new trends in theranostics;
2. Discuss how to disseminate innovative personalized medicine;
3. Discuss the economic and public health impact on advancing theranostic approaches. |
| 13:45-14:30 | Q&A |  |  |  |  |

## Session IV - Theranostics: The Way Forward

<table>
<thead>
<tr>
<th>Time (CEST)</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
<th>Learning Objectives</th>
</tr>
</thead>
</table>
| 12:45-13:15 | Where we are | Markus Luster | University of Marburg - Germany | In Vienna | 1. Discuss new trends in theranostics;
2. Discuss how to disseminate innovative personalized medicine;
3. Discuss the economic and public health impact on advancing theranostic approaches. |
| 13:15-13:45 | Where are we going? | Giuliano Mariani | University of Pisa - Italy | Remote access from Italy | 1. Discuss new trends in theranostics;
2. Discuss how to disseminate innovative personalized medicine;
3. Discuss the economic and public health impact on advancing theranostic approaches. |
| 13:45-14:30 | Q&A |  |  |  |  |

## Session I-B - Theranostic Applications in Prostate Cancer: Current Status and Trends

<table>
<thead>
<tr>
<th>Time (CEST)</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
<th>Location</th>
<th>Learning Objectives</th>
</tr>
</thead>
</table>
| 14:45-15:05 | What are the urologists’ needs? | Jochen Walz | Institut Paoli-Calmette - France | Remote access from France | 1. Understand the global burden of prostate cancer;
2. Assess the needs and expectations of referring physicians when requesting a PET/CT scan;
3. Discuss the clinician’s perspective in regard to the indications of radionuclide therapies (223 Radium and radiolabelled PSMA). |
| 15:05-15:25 | PSMA and beyond | Stefano Fantl | University of Bologna - Italy | Remote access from Italy | 1. Review the status of molecular imaging with regards to prostate cancer;
2. Discuss new approaches using personalized medicine for prostate cancer;
3. Analyse the impact of Ga-PSMA in the management of prostate cancer. |
| 15:25-15:45 | Alpha therapies | Mike Sathekge | University of Pretoria - South Africa | In Vienna | 1. Recognize the available radionuclide therapies for prostate cancer;
2. Analyse the different impacts in patient’s overall survival and disease-free survival;
3. Discuss the evidence-based data available. |
| 15:45-17:15 | Case review interactive session | Wim Oyen | Humanitas Milan - Italy | University of Pretoria - South Africa | In Vienna | 1. Practice relevant case scenarios;
2. Reconcile clinical knowledge with novel theranostic methods;
3. Demonstrate the role of theranostics in the management of prostate cancer. |
| 17:15-17:35 | Q&A |  |  |  |  |

## CLOSING

Diana Paez, IAEA